Search Results

On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group, announced that Enlituo®, a new generation anti-epidermal growth factor receptor antibody drug developed in collaboration with Mabpharm Limited, has recently received approval from the China National Medical Administration for marketing.

Simcere Pharmaceutical Group Limited entered into an exclusive license and collaboration agreement with Connect Biopharma HongKong Limited in relation to Rademikibart, an innovative IL-4Rα monoclonal antibody.

Connect Biopharma Holdings Limited announced that two of its wholly owned subsidiaries, Connect Biopharma Hong Kong Limited and Suzhou Connect Biopharma Co., Ltd., have entered into an exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Ltd., to develop and commercialize Connect Biopharma’s rademikibart in Greater China.

Simcere Pharmaceutical disclosed the latest progress on the company’s R&D and business operation on its first Investor Day themed “Focusing on more effective new products with differentiated clinical value” in Hong Kong.

Simcere Pharmaceutical Group Limited announced a Sponsored Research Agreement with Mass General Brigham.

Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) today announces that its wholly owned subsidiary Ascletis Pharmaceuticals Co., Ltd. has entered into a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096, “Simcere”).

Simcere Pharmaceutical Group（2096.HK), an innovation and R&D-driven pharmaceutical company, and Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health; announced today that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278.

Simcere Zaiming today announced two oral and six poster presentations will be presented on the Company’s preclinical programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, FL.

Almirall S.A. and Simcere Pharmaceutical Grou announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein autoimmune drug candidate, SIM0278.

The five-year investment will go toward the construction of a new R&D facility in Beijing to develop innovative therapies and integrate the world’s second most populated country into the company’s global strategy.